Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus
about
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsSaturated high-fat diet-induced obesity increases adenylate cyclase of myocardial β-adrenergic system and does not compromise cardiac function.Cardiovascular and hemodynamic effects of glucagon-like peptide-1.Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism.PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesMetabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth MuscleObesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism.GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in ratsCardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.Mechanisms for the cardiovascular effects of glucagon-like peptide-1.Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction.Cardiovascular effects of anti-diabetes drugs.Cardiovascular consequences of metabolic syndrome.Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia.Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.Is it time to reassess the role of myocardial metabolic modulation for the treatment of heart failure?Liraglutide protects cardiac function in diabetic rats through the PPARα pathway.Multiorgan, Multimodality Imaging in Cardiometabolic Disease.
P2860
Q26823085-F6A7E1ED-5E17-4487-B7F7-38D9F06100A2Q30392463-FE49F169-A0AB-4DD6-A42E-D23A2E1395BCQ33993725-9CFC5308-8D8F-4EB6-A424-FE23FEE74312Q34653078-5A2389E6-7482-4486-84E4-D8C62B14EB14Q34785887-0387BE40-7337-4B0E-AA8C-83864F5FBB3EQ34994502-0CB238B1-61E4-48BB-AE56-71BC4B5FFE57Q35973848-BB6629EB-5FBA-4574-B3F2-BB0605BD0121Q37468729-03CAC741-13B6-488D-9849-BD075C742DBBQ37510130-A7D4EDC8-96EF-4EBA-BA26-DF38192D0201Q37611715-FC80B7DE-8A72-445F-AE66-952EF310172FQ38218639-B6E1236F-D767-46D5-A5D7-608877E55F88Q38372787-10A5B959-2A73-4B0D-AB48-27530F5FE35BQ38589032-A9A0DB7F-4C88-4E07-8E7A-412ECA5BC847Q38797077-AD77D958-D804-4555-A108-4B1D3AC66A2BQ38857056-AF667DBB-D703-40BF-B390-03BA22165745Q39106973-867473D2-A453-48EE-837A-BB7EFDA4051FQ41853657-6413B5A5-B60B-4E4C-9185-E89FB3C52050Q41878782-240F9501-EF92-4B58-82EC-626581C48CC7Q49630529-3BBDD00E-5396-4252-9281-C5E318BF4212Q50026330-5D77CBB1-825E-4BA7-89A5-D5E979D6CE94Q50084370-7BDF14B2-CCDD-4A49-9415-AD141ACF17C6
P2860
Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impaired cardiometabolic respo ...... y and type 2 diabetes mellitus
@en
Impaired cardiometabolic respo ...... and type 2 diabetes mellitus.
@nl
type
label
Impaired cardiometabolic respo ...... y and type 2 diabetes mellitus
@en
Impaired cardiometabolic respo ...... and type 2 diabetes mellitus.
@nl
prefLabel
Impaired cardiometabolic respo ...... y and type 2 diabetes mellitus
@en
Impaired cardiometabolic respo ...... and type 2 diabetes mellitus.
@nl
P2093
P2860
P1476
Impaired cardiometabolic respo ...... y and type 2 diabetes mellitus
@en
P2093
Eli D Casalini
Gary D Hutchins
Kevin M Perry
Kieren J Mather
Mark A Green
Meredith K Owen
Robert V Considine
Robin L Chisholm
Steven P Moberly
P2860
P2888
P356
10.1007/S00395-013-0365-X
P577
2013-06-14T00:00:00Z